AI Article Synopsis

  • The study systematically reviews the effectiveness of medications for treating co-occurring mental health disorders in people with borderline personality disorder (BPD), using updated data from 22 trials.* -
  • Findings show very-low-certainty and low-certainty evidence for antipsychotics and anticonvulsants affecting depressive and anxious symptoms, but no significant benefit from antidepressants.* -
  • Overall, the evidence does not endorse the use of medications for co-occurring issues in BPD patients, and suggests that medications should be used carefully in these cases.*

Article Abstract

Background: Medications are commonly used to treat co-occurring psychopathology in persons with borderline personality disorder (BPD).

Aims: To systematically review and integrate the evidence of medications for treatment of co-occurring psychopathology in people with BPD, and explore the role of comorbidities.

Method: Building on the current Cochrane review of medications in BPD, an update literature search was done in March 2024. We followed the methods of this Cochrane review, but scrutinised all identified placebo-controlled trials for reporting of non BPD-specific ('co-occurring') psychopathology, and explored treatment effects in subgroups of samples with and without defined co-occurring disorders. GRADE ratings were done to assess the evidence certainty.

Results: Twenty-two trials were available for quantitative analyses. For antipsychotics, we found very-low-certainty evidence (VLCE) of an effect on depressive symptoms (standardised mean difference (SMD) -0.22, = 0.04), and low-certainty evidence (LCE) of an effect on psychotic-dissociative symptoms (SMD -0.28, = 0.007). There was evidence of effects of anticonvulsants on depressive (SMD -0.44, = 0.02; LCE) and anxious symptoms (SMD -1.11, < 0.00001; VLCE). For antidepressants, no significant findings were observed (VLCE). Exploratory subgroup analyses indicated a greater effect of antipsychotics in samples including participants with co-occurring substance use disorders on psychotic-dissociative symptoms ( = 0.001).

Conclusions: Our findings, based on VLCE and LCE only, do not support the use of pharmacological interventions in people with BPD to target co-occurring psychopathology. Overall, the current evidence does not support differential treatment effects in persons with versus without defined comorbidities. Medications should be used cautiously to target co-occurring psychopathology.

Download full-text PDF

Source
http://dx.doi.org/10.1192/bjp.2024.172DOI Listing

Publication Analysis

Top Keywords

co-occurring psychopathology
20
pharmacological interventions
8
psychopathology people
8
borderline personality
8
personality disorder
8
people bpd
8
cochrane review
8
treatment effects
8
psychotic-dissociative symptoms
8
symptoms smd
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!